[ 4 ] Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage Ⅲ colon cancer[J]. N Engl J Med, 2005, 352(26): 2696-2704.
[5]
[ 5 ] Twelves C, Gollins S, Grieve R, et al. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer[J]. Ann Oncol, 2006, 17(2): 239-245.
[6]
[ 6 ] Koukourakis GV, Kouloulias V, Koukourakis MJ, et al. Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review[J]. Molecules, 2008, 13(8): 1897-1922.
[7]
[ 8 ] Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stageⅢ colon cancer[J]. J Clin Oncol, 2011, 29(11): 1465-1471.
[8]
Patt YZ, Lee FC, Liebmann JE, et al. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phaseⅡ trial results[J]. Am J Clin Oncol, 2007, 30(4): 350-357.
[9]
Garcia-Alfonso P, Mu？oz-Martin A, Mendez-Ure？a M, et al. Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group[J]. Br J Cancer, 2009, 101(7): 1039-1043.
[10]
[ 7 ] Walko CM, Lindley C. Capecitabine: a review[J]. Clin Ther, 2005, 27(1): 23-44.
[11]
[ 9 ] Hsu TC, Chen HH, Yang MC, et al. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage Ⅲ colon cancer in Taiwan[J]. Value Health, 2011, 14(5): 647-651.
[12]
Borner MM, Bernhard J, Dietrich D, et al. A randomized phaseⅡ trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity[J]. Ann Oncol, 2005, 16(2): 282-288.
[13]
Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions Version 5.0.0[updated February 2008][EB/OL]. The Cochrane Collaboration, 2008. http://www.mrc-bsu.cam.ac.uk/cochrane/handbook500/.
[14]
Skof E, Rebersek M, Hlebanja Z, et al. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase Ⅱ trial[J]. BMC Cancer, 2009, 9(9): 120.
[15]
Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study[J]. J Clin Oncol, 2008, 26(4): 689-690.
[16]
K？hne CH, De Greve J, Hartmann JT, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015[J]. Ann Oncol, 2008, 19(5): 920-926.
[17]
Toxicity of fluorouracil in patients with advanced colorectal cancer:effect of administration schedule, factors P. Meta-Analysis group in cancer[J]. J Clin Oncol, 1998, 16(11): 3537-3541.
[18]
Zhang RX, Wu XJ, Lu SX, et al. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stageⅡ/Ⅲ colorectal cancer: a phaseⅡ randomized prospective study[J]. J Cancer Res Clin Oncol, 2011, 137(6): 953-957.
[19]
Kamil M, Haron M, Yosuff N, et al. High frequency of hand foot syndrome with capecitabine[J]. J Coll Physicians Surg Pak, 2010, 20(6): 421-422.
